- Home
- TNXP vs IGMS Comparison
TNXP vs IGMS Comparison
Compare TNXP & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- IGMS
- Stock Information
- Founded
- TNXP 2007
- IGMS 1993
- Country
- TNXP United States
- IGMS United States
- Employees
- TNXP N/A
- IGMS N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- TNXP Health Care
- IGMS Health Care
- Exchange
- TNXP Nasdaq
- IGMS Nasdaq
- Market Cap
- TNXP 71.6M
- IGMS 82.1M
- IPO Year
- TNXP N/A
- IGMS 2019
- Fundamental
- Price
- TNXP $18.18
- IGMS $1.17
- Analyst Decision
- TNXP Strong Buy
- IGMS Hold
- Analyst Count
- TNXP 2
- IGMS 8
- Target Price
- TNXP $585.00
- IGMS $6.14
- AVG Volume (30 Days)
- TNXP 2.6M
- IGMS 200.2K
- Earning Date
- TNXP 03-18-2025
- IGMS 03-06-2025
- Dividend Yield
- TNXP N/A
- IGMS N/A
- EPS Growth
- TNXP N/A
- IGMS N/A
- EPS
- TNXP N/A
- IGMS N/A
- Revenue
- TNXP $10,094,000.00
- IGMS $2,679,000.00
- Revenue This Year
- TNXP $84.08
- IGMS $134.71
- Revenue Next Year
- TNXP $126.94
- IGMS $74.27
- P/E Ratio
- TNXP N/A
- IGMS N/A
- Revenue Growth
- TNXP 29.94
- IGMS 25.77
- 52 Week Low
- TNXP $6.76
- IGMS $1.12
- 52 Week High
- TNXP $672.00
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- TNXP 48.95
- IGMS 33.91
- Support Level
- TNXP $12.80
- IGMS $1.17
- Resistance Level
- TNXP $31.87
- IGMS $1.31
- Average True Range (ATR)
- TNXP 4.30
- IGMS 0.08
- MACD
- TNXP 0.57
- IGMS 0.04
- Stochastic Oscillator
- TNXP 22.53
- IGMS 14.52
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.